Serological markers in inflammatory bowel disease

Immuno-Analyse et Biologie Specialisee

Volumn 23, Issue 6, 2008, Pages 358-367

  Vermeulen, N ^a   Vermeire, S ^a   Rutgeerts, P ^a   Bossuyt, X ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Autoantibodies; Inflammatory bowel Disease; Microbial antibodies

Indexed keywords

ANTIBODY; AUTOANTIGEN; BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; CHITOBIOSIDE CARBOHYDRATE IGA ANTIBODY; FLAGELLIN; GLYCAN ANTIBODY; GOBLET CELL AUTOANTIBODY; LAMINARIBIOSIDE CARBOHYDRATE IGG ANTIBODY; MANNOBIOSIDE CARBOHYDRATE IGG ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; OUTER MEMBRANE PORIN C ANTIBODY; PANCREATIC AUTOANTIBODY; PROTEIN CBIR1; TISSUE TYPE PLASMINOGEN ACTIVATOR ANTIBODY; TROPOMYOSIN ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ARTICLE; CROHN DISEASE; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; HUMAN; IMMUNE RESPONSE; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; PROGNOSIS; SACCHAROMYCES CEREVISIAE; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS;

EID: 57249108193     PISSN: 09232532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.immbio.2008.09.002     Document Type: Article

References (129)

1. Duerr R.H., Targan S.R., Landers C.J., Sutherland L.R., and Shanahan F. Anti-neutrophil cytoplasmic antibodies in ulcerative colitis. Comparison with other colitides/diarrheal illnesses. Gastroenterology 100 (1991) 1590-1596
2. Lennard-Jones J.E. Classification of inflammatory bowel disease. Scand J Gastroenterol suppl. 24 (1989) 2-6
3. IBD Section, British Society of Gastroenterology, Carter M.J., Lobo A.J., and Travis S.P. Guidelines for the management of inflammatory bowel disease in adults. Gut. 53 Suppl. 5 (2004 Sep) V1-V16
4. Vermeire S., Peeters M., and Rutgeerts P. Diagnostic approach to IBD. Hepatogastroenterology 47 (2000) 44-48
5. Sartor R.B. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease. Gastroenterol Clin North Am. 24 (1995) 475-507
6. Podolsky D.K. Inflammatory bowel disease. N Engl J Med. 325 (1991) 928-937 Review
7. Taylor K.D., Plevy S.E., Yang H., Landers C.J., Barry M.J., Rotter J.I., et al. ANCA pattern and HLA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology 120 (2001) 1347-1355
8. Davies D.J., Moran J.E., Niall J.F., and Ryan G.B. Segmental necrotizing glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology?. Br Med J 285 (1982) 606
9. Van der Woude F.J., Rasmussen N., Lobatto S., Wiik A., Permin H., van Es L.A., et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet i (1985) 425-429
10. Niles J.L., McCluskey R.T., Ahmad M.F., and Arnaout M.A. Wegener's granulomatosis autoantigen is a novel neutrophil serine proteinase. Blood 74 (1989) 1888-1893
11. Kallenberg C.G.M., Brouwer E., Weening J.J., and Cohen Tervaert J.W. Antineutrophil cytoplasmic antibodies: Current diagnostic and pathophysiological potential. Kidney Int 46 (1994) 1-15
12. Falk R.J., and Jennette J.C. Antineutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulone phritis. N Engl J Med 318 (1988) 1651-1657
13. Cohen Tervaert J.W., Van Der Woude F.J., Fauci A.S., Ambrus J.L., Velosa J., Keane W.F., et al. Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med 149 (1989) 2461-2465
14. Billing P., Tahir S., Calfin B., Gagne G., Cobb L., Targan S., et al. Nuclear localization of the antigen detected by ulcerative colitis-associated perinuclear antineutrophil cytoplasmic antibodies. Am J Pathol. 147 (1995) 979-987
15. Terjung B., Herzog V., Worman H.J., Gestmann I., Bauer C., Sauerbruch T., et al. Atypical antineurophil cytoplasmic antibodies with perinuclear fluoresence in chronic inflammatory bowel disease and hepatobiliary disorders colocalize with nuclear lamina proteins. Hepatology 28 (1998) 332-340
16. Rump J.A., Scholmerich J., Gross V., Roth M., Helfesrieder R., Rautmann A., et al. A new type of perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis but not in Crohn's disease. Immunobiology 181 (1990) 406-413
17. Lindgren S., Floren C.H., Lindhagen T., Starck M., Stewenius J., and Nassberger L. Low prevalence of antineutrophil cytoplasmic antibodies in ulcerative colitis patients with long-term remission. Eur J Gastroenterol Hepatol 7 (1995) 563-568
18. Roozendaal C., Pogany K., Hummel E.J., Horst G., Dijstra G., Nelis G.F., et al. Titers of antineutrophil cytoplasmic antibodies in inflammatory bowel disease are not related to disease activity. Q J Med 92 (1999) 651-658
19. Reumaux D., Colombel J.F., Masy E., Duclos B., Heresbach D., Belaiche J., et al. Antineutrophil cytoplasmic autoantibodies (ANCA) in ulcerative colitis (UC): no relationship with disease activity. Inflamm Bowel Dis 6 (2000) 270-274
20. Saxon A., Shanahan F., Landers C., Ganz T., and Targan S. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol 86 (1990) 202-210
21. Rutgeerts P., and Vermeire S. Clinical value of the detection of antibodies in the serum for diagnosis and treatment of inflammatory bowel disease. Gastroenterology 115 (1998) 1006-1022
22. Eggena M., Cohavy O., Parseghain M.H., Hamkalo B.A., Clemens D., Targan R.S., et al. Identification of Histone H1 as a cognate antigen of the ulcerative colitis-associated marker antibody pANCA. J Autoimmun 14 (2000) 83-97
23. Terjung B., Spengler U., Sauerbruch T., and Worman H.J. Atypical pANCA in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology 119 (2000) 310-322
24. Sobajima J., Ozaki S., Uesugi H., Osakada F., Shirakawa H., Yoshida M., et al. Prevalence and characterization of perinuclear antineutrophil cytoplasmic antibodies (pANCA) directed against HMG1 and HMG2 in ulcerative colitis (UC). Clin Exp Immunol. 111 (1998) 402-407
25. Roozendaal C., Zhao M.H., Horst G., Lockwood C.M., Kleibeuker J.H., Limburg P.C., et al. Catalase and alpha-enolase: two novel granulocyte autoantigens in inflammatory bowel disease (IBD). Clin Exp Immunol 112 (1998) 10-16
26. Peen E., Almer S., Bodemar G., Ryden B.O., Sjolin C., Tejle K., et al. Antilactoferrin antibodies and other types of ANCA in ulcerative colitis, primary sclerosing cholangitis, and Crohn's disease. Gut 34 (1993) 56-62
27. Nässberger L., Ljungh A., Schumacher G., and Kollberg B. β-Glucuronidase antibodies in ulcerative colitis [Letter]. Lancet 340 (1993) 734-735
28. Schmitt W.H., Csernok E., Flesch B.K., Hauschild S., and Gross W.L. Autoantibodies directed against lysozyme: a new target antigen for antineutrophil cytoplasmic antibodies (ANCA). Adv Exp Med Biol. 336 (1993) 267-272
29. Duerr R.H., Targan S.R., Landers C.J., LaRusso N.F., Lindsay K.L., Wiesner R.H., et al. Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology. 100 (1991) 1385-1391
30. Sobajima J., Ozaki S., Okazaki T., Osakada F., Sumita S., Mori K., et al. Antineutrophil cytoplasmic antibodies (ANCA) in ulcerative colitis: anticathepsin G and a novel antibody correlate with a refractory type. Clin Exp Immunol 105 (1996) 120-124
31. Stoffel M.P., Csernok E., Herzberg C., Johnson T., Carroll S.F., and Gross W.L. Antineutrophil cytoplasmic antibodies (ANCA) directed against bactericidal/permeability increasing protein (BPI): a new seromarker for inflammatory bowel disease and associated disorders. Clin Exp Immunol 104 (1996) 54-59
32. Walmsley R.S., Zhao M.H., Hamilton M.I., Brownlee A., Chapman P., Pounder R.E., et al. Antineutrophil cytoplasm autoantibodies against bactericidal/permeability-increasing protein in inflammatory bowel disease. Gut 40 (1997) 105-109
33. Bossuyt X. Serologic markers in inflammatory bowel disease. Clin Chem 52 (2006) 171-181
34. Terjung B., and Worman H.J. Antineutrophil antibodies in primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 15 (2001) 629-642
35. Terjung B., Bogsch F., Klein R., Sohne J., Reichel C., Wasmuth J.C., et al. Diagnostic accuracy of atypical pANCA in autoimmune hepatitis using ROC- and multivariate regression analysis. Eur J Med Res 9 (2004) 439-448
36. Sandborn W.J., Landers C.J., Tremaine W.J., and Targan S.R. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc 71 (1996) 431-436
37. Yang P., Bohr J., Tysk C., Danielsson D., and Järnerot G. Antineutrophil cytoplasmic antibodies in inflammatory bowel disease and collagenous colitis: no association with lactoferrin, ß-glucuronidase, myeloperoxidase, or proteinase-3. Inflamm Bowel Dis 2 (1996) 173-177
38. Vecchi M., Gionchetti P., Bianchi M.B., Belluzzi A., Meucci G., Campieri M., et al. pANCA and development of pouchitis in ulcerative colitis patients after proctocolectomy and ileoanal pouch anastomosis. Lancet 344 (1994) 886-887
39. Sandborn W.J., Landers C.J., Tremaine W.J., and Targan S.R. Antineutrophil cytoplasmic antibody correlates with chronic pouchitis after ileal pouch-anal anastomosis. Am J Gastroenterol 90 (1995) 740-747
40. Esteve M., Mallolas J., Klaassen J., Abad-Lacruz A., González-Huix F., Cabré E., et al. Antineutrophil cytoplasmic antibodies in sera from colectomised ulcerative colitis patients and its relation to the presence of pouchitis. Gut 38 (1996) 894-898
41. Brett P.M., Yasuda N., Yiannakou J.Y., Herbst F., Ellis H.J., Vaughan R., et al. Genetic and immunological markers in pouchitis. Eur J Gastroenterol Hepatol 8 (1996) 951-955
42. Vasiliauskas E.A., Plevy S.E., Landers C.J., Binder S.W., Ferguson D.M., Yang H., et al. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology 110 (1996) 1810-1819
43. Jamar-Leclerc N., Reumaux D., Duthilleul P., and Colombel J.F. Do pANCA define a clinical subgroup in patients with Crohn's disease?. Gastroenterology. 112 (1997) 316-317
44. Mulder A.H., Broekroelofs J., Horst G., Limburg P.C., Nelis G.F., and Kallenberg C.G. Antineutrophil cytoplasmic antibodies (ANCA) in inflammatory bowel disease: characterization and clinical correlates. Clin Exp Immunol 95 (1994) 490-497
45. Abad E., Tural C., Mirapeix E., and Cuxart A. Relationship between ANCA and clinical activity in inflammatory bowel disease: variation in prevalence of ANCA and evidence of heterogeneity. J Autoimmun. 10 (1997) 175-180
46. Bansi D.S., Chapman R.W., and Fleming K.A. Prevalence and diagnostic role of antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Eur J Gastroenterol Hepatol 8 (1996) 881-885
47. Kossa K., Coulthart A., Ives C.T., Pusey C.D., and Hodgson H.J. Antigen specificity of circulating anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease. Eur J Gastroenterol Hepatol 7 (1995) 783-789
48. Oudkerk Pool M., Ellerbroek P.M., Ridwan B.U., Goldschmeding R., von Blomberg B.M., Peña A.S., et al. Serum antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease are mainly associated with ulcerative colitis. A correlation study between perinuclear antineutrophil cytoplasmic autoantibodies and clinical parameters, medical, and surgical treatment. Gut 34 (1993) 46-50
49. Schumacher G., Kollberg B., Sandstedt B., Ljungh A., and Nässberger L. Circulating granulocyte antibodies in first attacks of colitis. Scand J Gastroenterol. 30 (1995) 157-163
50. Brimnes J., Nielsen O.H., Wiik A., and Heegaard N.H. Autoantibodies to molecular targets in neutrophils in patients with ulcerative colitis. Dig Dis Sci 44 (1999) 415-423
51. Joossens S., Daperno M., Shums Z., Van Steen K., Goeken J.A., Trapani C., et al. Interassay and interobserver variability in the detection of antineutrophil cytoplasmic antibodies in patients with ulcerative colitis. Clin Chem 50 (2004) 1422-1425
52. Stöcker W., Otte M., Ulrich S., Normann D., Stöcker K., and Jantschek G. Autoantibodies against the exocrine pancreas and against intestinal goblet cells in the diagnosis of Crohn's disease and ulcerative colitis. Deutsch Med Wochenschr 109 (1984) 1963-1969
53. Stöcker W., Otte M., Ulrich S., Normann D., Finkbeiner H., Stöcker K., et al. Autoimmunity to pancreatic juice in Crohn's disease. Results of an autoantibody screening in patients with chronic inflammatory bowel disease. Scand J Gastroenterol suppl. 139 (1987) 41-52
54. Seibold F., Weber P., Jenss H., and Wiedmann K.H. Antibodies to a trypsin sensitive pancreatic antigen in chronic inflammatory bowel disease: specific markers for a subgroup of patients with Crohn's disease. Gut 32 (1991) 1192-1197
55. Folwaczny C., Noehl N., Endres S.P., Loeschke K., and Fricke H. Antineutrophil and pancreatic autoantibodies in first-degree relatives of patients with inflammatory bowel disease. Scand J Gastroenterol 33 (1998) 523-528
56. Klebl F.H., Bataille F., Huy C., Hofstädter F., Schölmerich J., and Rogler G. Association of antibodies to exocrine pancreas with subtypes of Crohn's disease. Eur J Gastroenterol Hepatol 17 (2005) 73-77
57. Joossens S., Vermeire S., Van Steen K., Godefridis G., Claessens G., Pierik M., et al. Pancreatic autoantibodies in inflammatory bowel disease. Inflamm Bowel Dis 10 (2004) 771-777
58. Fricke H., Birkhofer A., Folwaczny C., Meister W., and Scriba P.C. Characterization of antigens from the human exocrine pancreatic tissue (Pag) relevant as target antigens for autoantibodies in Crohn's disease. Eur J Clin Invest 29 (1999) 41-45
59. Desplat-Jégo S., Johanet C., Escande A., Goetz J., Fabien N., Olsson N., et al. Update on anti-Saccharomyces cerevisiae antibodies, antinuclear associated antineutrophil antibodies and antibodies to exocrine pancreas detected by indirect immunofluorescence as biomarkers in chronic inflammatory bowel diseases: results of a multicenter study. World J Gastroenterol 13 (2007) 2312-2318
60. Seibold F., Scheurlen M., Müller A., Jenss H., and Weber P. Impaired pancreatic function in patients with Crohn's disease with and without pancreatic autoantibodies. J Clin Gastroenterol 22 (1996) 202-206
61. Herrlinger K.R., and Stange E.F. The pancreas and inflammatory bowel diseases. Int J Pancreatol 27 (2000) 171-179 Review
62. Weber P., Seibold F., and Jenss H. Acute pancreatitis in Crohn's disease. J Clin Gastroenterol 17 (1993) 286-291
63. Broberger O., and Perlmann P. Autoantibodies in human ulcerative colitis. J Exp Med 110 (1959) 657-674
64. Hibi T., Ohara M., Kobayashi K., Brown W.R., Toda K., Takaishi H., et al. Enzyme linked immunosorbent assay (ELISA) and immunoprecipitation studies on anti-goblet cell antibody using a mucin producing cell line in patients with inflammatory bowel disease. Gut 35 (1994) 224-230
65. Folwaczny C., Noehl N., Tschöp K., Endres S.P., Heldwein W., Loeschke K., et al. Goblet cell autoantibodies in patients with inflammatory bowel disease and their first-degree relatives. Gastroenterology 113 (1997) 101-106
66. Lawrance I.C., Hall A., Leong R., Pearce C., and Murray K. A comparative study of goblet cell and pancreatic exocine autoantibodies combined with ASCA and pANCA in Chinese and Caucasian patients with IBD. Inflamm Bowel Dis 11 (2005) 890-897
67. Castro-Santos P., Suarez A., Mozo L., and Gutierrez C. Association of IL-10 and TNFalpha genotypes with ANCA appearance in ulcerative colitis. Clin Immunol 122 (2007) 108-114
68. Das K.M., Dubin R., and Nagai T. Isolation and characterization of colonic tissue-bound antibodies from patients with idiopathic ulcerative colitis. Proc Natl Acad Sci USA 74 (1978) 4528-4532
69. Takahashi F., and Das K.M. Isolation and characterization of a colonic autoantigen specifically recognized by colon tissue-bound IgG from idiopathic ulcerative colitis. J Clin Invest 76 (1985) 311-318
70. Das K.M., Dasgupta A., Mandal A., and Geng X. Autoimmunity to cytoskeletal protein tropomyosin(s): a new clue to the pathogenic mechanism for ulcerative colitis. J Immunol 150 (1993) 2487-2493
71. Lin J.J.-C., Warren K.S., and Wambolt D. Tropomyosin isoforms in nonmuscle cells. Int Rev Cytol 170 (1997) 1-38
72. Biancone L., Monteleone G., Marasco R., and Pallone F. Autoimmunity to tropomyosin isoforms in ulcerative colitis (UC) patients and unaffected relatives. Clin Exp Immunol 113 (1998) 198-205
73. Mirza Z.K., Sastri B., Lin J.J., Amenta P.S., and Das K.M. Autoimmunity against human tropomyosin isoforms in ulcerative colitis: localization of specific human tropomyosin isoforms in the intestine and extraintestinal organs. Inflamm Bowel Dis 12 (2006) 1036-1043
74. Gris J.C., Schved J.F., Raffanel C., Dubois A., Aguilar-Martinez P., Arnaud A., et al. Impaired fibrinolytic capacity in patients with inflammatory bowel disease. Thromb Haemost 63 (1990) 472-475
75. Saibeni S., Ciscato C., Vecchi M., Boscolo Anzoletti M., Kaczmarek E., Caccia S., et al. Antibodies to tissue-type plasminogen activator (t-PA) in patients with inflammatory bowel disease: high prevalence, interactions with functional domains of t-PA and possible implications in thrombosis. J Thromb Haemost 4 (2006) 1510-1516
76. Main J., McKenzie H., Yeaman G.R., Kerr M.A., Robson D., Pennington C.R., et al. Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease. Br Med J 297 (1988) 1105-1106
77. Quinton J.F., Sendid B., Reumaux D., Duthilleul P., Cortot A., Grandbastien B., et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 42 (1998) 788-791
78. Muratori P., Muratori L., Guidi M., Maccariello S., Pappas G., Ferrari R., et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases. Clin Exp Immunol 132 (2003) 473-476
79. Sendid B., Colombel J.F., Jacquinot P.M., Faille C., Fruit J., Cortot A., et al. Specific antibody response to oligomannosidic epitopes in Crohn's disease. Clin Diagn Lab Immunol 3 (1996) 219-226
80. Halfvarson J., Standaert-Vitse A., Järnerot G., Sendid B., Jouault T., Bodin L., et al. Anti-Saccharomyces cerevisiae antibodies in twins with inflammatory bowel disease. Gut 54 (2005) 1237-1243
81. Walker L.J., Aldhous M.C., Drummond H.E., Smith B.R., Nimmo E.R., Arnott I.D., et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutations. Clin Exp Immunol 135 (2004) 490-496
82. Vasiliauskas A., Kam L.Y., Karp L.C., Giaennie J., Yang H., and Targan S.R. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 47 (2000) 487-496
83. Saibeni S., Folli C., de Franchis R., Borsi G., and Vecchi M. Diagnostic role and clinical correlates of anti-Saccharomyces cerevisiae antibodies (ASCA) and antineutrophil cytoplasmic antibodies (pANCA) in Italian patients with inflammatory bowel diseases. Dig Liver Dis 35 (2003) 862-868
84. Sendid B., Quinton J.F., Charrier G., et al. Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohn's disease. Am J Gastroenterol 93 (1998) 1306-1310
85. Oshitani N., Hato F., Matsumoto T., Jinno Y., Sawa Y., Hara J., et al. Decreased anti-Saccharomyces cerevisiae antibody titer by mesalazine in patients with Crohn's disease. J Gastroenterol Hepatol 15 (2000) 1400-1403
86. Seibold F., Stich O., Hufnagl R., Kamil S., and Scheurlen M. Anti-Saccharomyces cerevisiae antibodies in inflammatory bowel disease: a family study. Scand J Gastroenterol 36 (2001) 196-201
87. Sutton C.L., Yang H., Li Z., Rotter J.I., Targan S.R., and Braun J. Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease. Gut 46 (2000) 58-63
88. Annese V., Andreoli A., Andriulli A., Dinca R., Gionchetti P., Latiano A., et al. Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in Crohn's disease and ulcerative colitis: a GISC study. Am J Gastroenterol 96 (2001) 2407-2412
89. Vermeire S., Peeters M., Vlietinck R., Joossens S., Den Hond E., Bulteel V., et al. Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm Bowel Dis 7 (2001) 8-15
90. Dotan N., Altstock R.T., Schwarz M., and Dukler A. Antiglycan antibodies as biomarkers for diagnosis and prognosis. Lupus 15 (2006) 442-450 Review
91. Ferrante M., Henckaerts L., Joossens M., Pierik M., Joossens S., Dotan N., et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 56 (2007) 1394-1403
92. Dotan I., Fishman S., Dgani Y., Schwartz M., Karban A., Lerner A., et al. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease. Gastroenterology 131 (2006) 366-378
93. Malickova K., Lukas M., Donoval R., Sandova P., and Janatkova I. Novel anticarbohydrate autoantibodies in patients with inflammatory bowel disease: are they useful for clinical practice?. Clin Lab 52 (2006) 631-638
94. Cohavy O., Bruckner D., Gordon L.K., Misra R., Wei B., Eggena M.E., et al. Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect Immun 68 (2000) 1542-1548
95. Landers C.J., Cohavy O., Misra R., Yang H., Lin Y.C., Braun J., et al. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology 123 (2002) 689-699
96. Papp M., Altorjay I., Norman G.L., Shums Z., Palatka K., Vitalis Z., et al. Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients. Inflamm Bowel Dis 13 (2007) 984-992
97. Jaskowski T.D., Litwin C.M., and Hill H.R. Analysis of serum antibodies in patients suspected of having inflammatory bowel disease. Clin Vaccine Immunol 13 (2006) 655-660
98. Lodes M.J., Cong Y., Elson C.O., Mohamath R., Landers C.J., Targan S.R., et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 113 (2004) 1296-1306
99. Targan S.R., Landers C.J., Yang H., Lodes M.J., Cong Y., Papadakis K.A., et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology 128 (2005) 2020-2028
100. Papadakis K.A., Yang H., Ippoliti A., Mei L., Elson C.O., Hershberg R.M., et al. Antiflagellin (CBir1) phenotypic and genetic Crohn's disease associations. Inflamm Bowel Dis 13 (2007) 524-530
101. Dalwadi H., Wei B., Kronenberg M., Sutton C.L., and Braun J. The Crohn's disease-associated bacterial protein I2 is a novel enteric t cell superantigen. Immunity 15 (2001) 149-158
102. Wei B., Huang T., Dalwadi H., Sutton C.L., Bruckner D., and Braun J. Pseudomonas fluorescens encodes the Crohn's disease-associated I2 sequence and T-cell superantigen. Infect Immun 70 (2002) 6567-6575
103. Sutton C.L., Kim J., Yamane A., Dalwadi H., Wei B., Landers C., et al. Identification of a novel bacterial sequence associated with Crohn's disease. Gastroenterology 119 (2000) 23-31
104. Arnott I.D., Landers C.J., Nimmo E.J., Drummond H.E., Smith B.K., Targan S.R., et al. Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol 99 (2004) 2376-2384
105. Mow W.S., Vasiliauskas E.A., Lin Y.C., Fleshner P.R., Papadakis K.A., Taylor K.D., et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 126 (2004) 414-424
106. Spivak J., Landers C.J., Vasiliauskas E.A., Abreu M.T., Dubinsky M.C., Papadakis K.A., et al. Antibodies to I2 predict clinical response to fecal diversion in Crohn's disease. Inflamm Bowel Dis 12 (2006) 1122-1130
107. Kobayashi K., Brown W.R., Brennan P.J., and Blaser M.J. Serum antibodies to mycobacterial antigens in active Crohn's disease. Gastroenterology 94 (1988) 1404-1411
108. Shafran I., Piromalli C., Decker J.W., Sandoval J., Naser S.A., and El-Zaatari F.A. Seroreactivities against Saccharomyces cerevisiae and Mycobacterium avium subsp. paratuberculosis p35 and p36 antigens in Crohn's disease patients. Dig Dis Sci 47 (2002 Sep) 2079-2081
109. Nakase H., Nishio A., Tamaki H., Matsuura M., Asada M., Chiba T., et al. Specific antibodies against recombinant protein of insertion element 900 of Mycobacterium avium subspecies paratuberculosis in Japanese patients with Crohn's disease. Inflamm Bowel Dis 12 (2006) 62-69
110. Saitoh S., Noda S., Aiba Y., Takagi A., Sakamoto M., Benno Y., et al. Bacteroides ovatus as the predominant commensal intestinal microbe causing a systemic antibody response in inflammatory bowel disease. Clin Diagn Lab Immunol 9 (2002) 54-59
111. Devlin S.M., Yang H., Ippoliti A., Taylor K.D., Landers C.J., Su X., et al. NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives. Gastroenterology 132 (2007) 576-586
112. Henckaerts L., Pierik M., Joossens M., Ferrante M., Rutgeerts P., and Vermeire S. Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease. Gut 56 (2007) 1536-1542
113. Ruemmele F.M., Targan S.R., Levy G., Dubinsky M., Braun J., and Seidman E.G. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology 115 (1998) 822-829
114. Hoffenberg E.J., Fidanza S., and Sauaia A. Serologic testing for inflammatory bowel disease. J Pediatr 134 (1999) 447-452
115. Conrad K., Schmechta H., Klafki A., Lobeck G., Uhlig H.H., Gerdi S., et al. Serological differentiation of inflammatory bowel diseases. Eur J Gastroenterol Hepatol 14 (2002) 129-135
116. Peeters M., Joossens S., Vermeire S., Vlietinck R., Bossuyt X., and Rutgeerts P. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 96 (2001) 730-734
117. Koutroubakis I.E., Petinaki E., Mouzas I.A., Vlachonikolis I.G., Anagnostopoulou E., Castanas E., et al. Anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic autoantibodies in Greek patients with inflammatory bowel disease. Am J Gastroenterol 96 (2001) 449-454
118. Lawrance I.C., Murray K., Hall A., Sung J.J., and Leong R. A prospective comparative study of ASCA and pANCA in Chinese and Caucasian IBD patients. Am J Gastroenterol 99 (2004) 2186-2194
119. Sandborn W.J., Loftus Jr. E.V., Colombel J.F., Fleming K.A., Seibold F., Homburger H.A., et al. Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease. Inflamm Bowel Dis 7 (2001) 192-201
120. Reese G.E., Constantinides V.A., Simillis C., Darzi A.W., Orchard T.R., Fazio V.W., et al. Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am J Gastroenterol 101 (2006) 2410-2422
121. Stewenius J., Adnerhill I., Ekelund G., FIoren C.-H., Fork F.-T., Janzon L., et al. Operations in unselected patients with ulcerative colitis and indeterminate colitis: a long-term follow-up study. Eur J Surg 162 (1996) 131-137
122. Mclntyre B.P., Pemberton J.H., Wolff B.G., Dozois R.R., and Beart R.W. Indeterminate colitis: long-term outcome in patients after ileal pouch-anal anastomosis. Dis Colon Rectum 38 (1995) 51-54
123. Atkinson K.G., Owen D.A., and Wankling G. Restorative proctocolectomy and indeterminate colitis. Am J Surg 167 (1994) 516-518
124. Joossens S., Reinisch W., Vermeire S., Sendid B., Poulain D., Peeters M., et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 122 (2002) 1242-1247
125. Joossens S., Colombel J.F., Landers C., Poulain D., Geboes K., Bossuyt X., et al. Anti-outer membrane of porin C and anti-I2 antibodies in indeterminate colitis. Gut 55 (2006) 1667-1669
126. Western Regional Pediatric IBD Research Alliance, Dubinsky M.C., Lin Y.C., Dutridge D., Picornell Y., Landers C.J., Farrior S., et al. Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am J Gastroenterol 101 (2006) 360-367
127. Dubinsky MC et al; Western Regional Pediatric IBD Research Alliance, Pediatric IBD Collaborative Research Group, and The Wisconsin Pediatric IBD Alliance. Increased Immune Reactivity Predicts Aggressive Complicating Crohn's Disease in Children. Clin Gastroenterol Hepatol. 2008 Jul 9.[Epub ahead of print].
128. Devlin S.M., and Dubinsky M.C. Determination of serologic and genetic markers aid in the determination of the clinical course and severity of patients with IBD. Inflamm Bowel Dis 14 (2008) 125-128 discussion 132-3
129. Xue S., Stempak J.M., Elkadri A.A., et al. Serological markers are associated with severity of disease and need for surgery in IBD patients. Gastroenterology 130 (2006) S1303